Healthcare Wrap: Trial Shock Hits Cynata as Diagnostics and Alzheimer’s Progress Lift Peers

• Cynata recorded the week’s biggest move as trading resumed after key trial results.
• INOVIQ, BCAL and CLINUVEL rose on research interest, new test data and a planned Nasdaq upgrade.
• Paradigm and Actinogen advanced on trial progress, while Racura locked in funding for three cancer studies.
• Microba and Vitrafy fell after capital raising plans, showing investors still punish dilution when near-term revenue is unclear.